Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand, $^{177}$Lu-DOTA-PSMA-GUL, in rats by using LC–MS/MS

Chang Ho Song1, Kweon Kim2, Eunhee Kang2, Bora Jeong2, Myung-Su Lee2, Jiyoon Jung2, Tae Hwan Kim3, Soyoung Shin4 & Beom Soo Shin1*

Prostate specific membrane antigen (PSMA) is known to be overexpressed in prostate cancer cells, providing as a diagnostic and therapeutic target for prostate cancer. A lutetium-labeled PSMA targeted ligand, $^{177}$Lu-DOTA-PSMA-GUL is a novel radiopharmaceutical, which has been developed for the treatment of prostate cancer. While the GUL domain of $^{177}$Lu-DOTA-PSMA-GUL binds to the antigen, the beta-emitting radioisotope, $^{177}$Lu-labeled DOTA, interacts with prostate cancer cells. However, the in vivo pharmacokinetics of intact $^{177}$Lu-DOTA-PSMA-GUL has never been characterized. This study aimed to evaluate the pharmacokinetics and tissue distribution of the radiopharmaceutical in rats by using its stable isotope-labeled analog, $^{175}$Lu-DOTA-PSMA-GUL. A sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis of $^{175}$Lu-DOTA-PSMA-GUL was developed and validated. Following intravenous injection, the plasma concentration-time profiles of $^{175}$Lu-DOTA-PSMA-GUL showed a multi-exponential decline with the average elimination half-life of 0.30 to 0.33 h. Systemic exposure increased with the dose and renal excretion is the major elimination route. Tissue distribution of $^{175}$Lu-DOTA-PSMA-GUL was most substantial in kidneys, followed by the prostate. The developed LC–MS/MS assay and the in vivo pharmacokinetic data of $^{175}$Lu-DOTA-PSMA-GUL would provide helpful information for further clinical studies to be developed as a novel therapeutic agent for prostate cancer.

Prostate cancer is one of the most commonly occurring cancers worldwide. In 2020, there were more than 1.41 million new reported cases and approximately 375,000 deaths related to prostate cancer globally1. Although advances in the diagnosis and treatment have improved the ability to stratify patients by risk2, the mortality rate for prostate cancer has not been significantly reduced. In particular, as the incidence and mortality rates of prostate cancer are strongly related to age3, prostate cancer can threaten more people’s lives with the aging trend of the population4.

As an effective prostate cancer biomarker, prostate-specific membrane antigen (PSMA) has become an emerging diagnostic and therapeutic target. Originally found on the membrane of the prostate epithelium, PSMA is also detected in normal tissue cells like the prostate, kidneys, and small intestine5. However, PSMA is significantly overexpressed in prostate cancer cells compared to the level of antigen expression at other carcinoma tissues6. Moreover, PSMA overexpression is associated with higher prostate cancer grades and is of interest as a predictor of prostate cancer progression7. Thus, targeting agents for PSMA have been extensively investigated and developed for the diagnosis as well as treatment of prostate cancer8–10.

Among various PSMA targeting agents, the urea-based PSMA ligand is one of the most advanced drug categories for imaging and therapy10. The urea-based PSMA ligands usually apply glutamate-urea-lysine (GUL) as a specific binding motif to PSMA. Representative GUL-based therapeutic PSMA ligands include $^{131}$I-MIP-1095, radionuclide-labeled PSMA-617, and PSMA-I&T. Particularly, $^{177}$Lu-PSMA-617 is one of the most studied

---

1School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi 16419, Republic of Korea. 2CellBion Co., Ltd., Seoul, Korea. 3College of Pharmacy, Daegu Catholic University, Gyeongsan, Korea. 4College of Pharmacy, Wonkwang University, Iksan, Korea. 5email: bsshin@skku.edu
Radioligands currently under development with the high affinity for PSMA, $^{177}$Lu-PSMA-617 has shown promising results in the early clinical studies and demonstrated its activity in patients in recently completed phase 3 trials. Radiotherapy with $^{177}$Lu-PSMA-617 also improved the overall survival and progression-free survival in mCRPC patients. The safety and efficacy of $^{177}$Lu-PSMA-617 have also been confirmed by a long-term follow-up study. In March 2022, $^{177}$Lu-PSMA-617 was finally approved by the FDA for the treatment of mCRPC. $^{177}$Lu-DOTA-PSMA-GUL is a structural analog of $^{177}$Lu-PSMA-617, developed to treat prostate cancer (Fig. 1). Both $^{177}$Lu-PSMA-617 and $^{177}$Lu-DOTA-PSMA-GUL have the GUL motif for specific binding to PSMA and the chelator 1,4,7,10-tetraazaacyclododecane-1,4,7,10-tetraacetic acid (DOTA) complexed with a radionuclide, $^{177}$Lu, connected by a linker.

However, despite the extensive research interests and therapeutic potential, the in vivo pharmacokinetics and tissue distribution of the intact PSMA targeting ligands have not been fully characterized. The radioactivity study showed that $^{177}$Lu-PSMA-617 was initially distributed into extracellular body water and eliminated biexponentially with the elimination half-life of 90 h in humans. High uptake and retention of radiation of these PSMA ligands in the tumors and PSMA expressing normal tissues have been observed. However, these are dosimetry studies that estimate the radiation doses in target tissues or rely on imaging techniques such as PET/CT, rather than quantifying the intact ligands. The major limitation in these radioactivity assays and imaging techniques is the inability to discern if the radionuclide is located in the intact drug or in the metabolites. Thus, these methods are primarily indirect and likely affected by other factors. There are no reports related to the pharmacokinetic information on the radioligands or their analogs by quantitively determining its intact concentration in the biological samples. The direct and quantitative evaluation of the pharmacokinetics and tissue distribution has never been pursued for any PSMA ligands or analogs.

The main obstacle for complete pharmacokinetic characterization of the radiopharmaceuticals is mainly attributed to their inherent radioactivity. Radioactive compounds need to be treated only in dedicated spaces and facilities. Safety concerns also arise with the experiments with radioactivity, which makes it difficult to be combined with common analytical techniques like high-performance liquid chromatography (HPLC) or mass spectrometry. Particularly, sample pretreatment to extract the analyte from the biological samples for conventional analysis often requires elaborate steps and longer time. Thus, the pharmacokinetic information of radiopharmaceuticals relies on the easy alternative, i.e., radioactivity measurement. In the case of PSMA targeted ligands, their complex structures also contributed to the analytical difficulties. Although mass spectrometry-based and HPLC methods have been applied for quality control purposes, analytical methods that can accurately determine the concentration of PSMA targeted ligands in the biological fluids are not available.

Therefore, this study aimed to evaluate the pharmacokinetics and tissue distribution of the radiopharmaceutical $^{177}$Lu-DOTA-PSMA-GUL by using its radio-inactive analog, $^{175}$Lu-DOTA-PSMA-GUL in rats. A sensitive and robust liquid-chromatography tandem mass spectrometry (LC–MS/MS) for the quantification of $^{177}$Lu-DOTA-PSMA-GUL has been developed and validated in the biological matrices including plasma, urine, feces, and twelve different tissues to evaluate its pharmacokinetics and tissue distribution properties in rats. Stable isotopes combined with mass spectrometry have been effectively applied to determine pharmacokinetics or mode of action particularly when the conventional approach is not feasible. This study might be the first report on the full characterization of the pharmacokinetics of an intact PSMA targeted ligand by applying mass spectrometry. The present LC–MS/MS analysis and the in vivo pharmacokinetic data of $^{175}$Lu-DOTA-PSMA-GUL may provide helpful information for the further development of Lu-labeled radiopharmaceuticals.

Figure 1. Structure of a Lu-labeled PSMA-targeted ligand, Lutetium labeled-1,4,7,10-tetraazaacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-PSMA-GUL.
Materials and methods

Materials. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-PSMA-GUL (99.0%), 1,4,7-triazaacyclononane-1,4,7-triacetic acid (NOTA)-PSMA-GUL (99.3%), and $^{175}$LuCl$_3$ (99.9%) were obtained from CellBion (Seoul, Korea). Esomeprazole, sodium acetate, and acetic acid were purchased from Sigma Aldrich Chemical Co. (Milwaukee, WI, USA). Hydrochloric acid was obtained from Samchun Chemical Co., Ltd (Seoul, Korea). High-performance liquid chromatography (HPLC) grade acetonitrile, methanol, and water were purchased from J.T. Baker Co. (Phillipsburg, NJ, USA).

Preparation of $^{175}$Lu-DOTA-PSMA-GUL solution. The drug solution of $^{175}$Lu-DOTA-PSMA-GUL was prepared according to the method provided by Cellbion Co. (Seoul, Korea). Briefly, $^{175}$Lu-DOTA-PSMA-GUL was synthesized by mixing DOTA-PSMA-GUL solution and $^{175}$LuCl$_3$ solution. DOTA-PSMA-GUL solution was prepared by dissolving 50 mg of DOTA-PSMA-GUL powder in 20 mL of 0.5 M sodium acetate buffer (pH 4.5). $^{175}$LuCl$_3$ solution was prepared by dissolving 19 mg of $^{175}$LuCl$_3$ in 10 mL of 0.04 M HCl. Then, 20 mL of $^{175}$Lu-DOTA-PSMA-GUL and 8.5 mL of $^{175}$LuCl$_3$ were mixed for 20 min at 40 °C in a shaking water bath. The mixture was finally tested for the purity of $^{175}$Lu-DOTA-PSMA-GUL via HPLC–UV method using Waters 2695 separation module coupled with Waters 2487 dual wavelength absorbance detector (Waters, Milford, MA, USA). $^{175}$Lu-DOTA-PSMA-GUL was separated on an Agilent Zorbax 300SB-C18 (4.6 × 250 mm i.d., 5 μm, Agilent, Santa Clara, CA, USA) and detected at 244 nm.

LC–MS/MS analysis condition. Liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis was performed by an Agilent 6490 triple-quadrupole mass spectrometer coupled with an Agilent 1260 HPLC (Agilent Technologies, Santa Clara, CA, USA). $^{175}$Lu-DOTA-PSMA-GUL in the rat biometrics (plasma, urine, feces, and 12 different tissue samples) was separated on an Agilent Zorbax SB-Aq column (100 × 2.1 mm, i.d., 3.5 μm, Agilent). Chromatographic separations were performed by using a binary gradient mobile phase composed of mobile phase A (1% formic acid in distilled water) and mobile phase B (1% formic acid in methanol). The gradient elution profile and flow rate was set as: 0 min, A:B = 95:5 (v/v), 0.3 mL/min; 8 min, 0:100, 0.3 mL/min; 10 min, 0:100, 0.3 mL/min; 10.01 min, 95:5, 0.5 mL/min; 15 min, 100:0, 0.5 mL/min; 15.01 min, 95:5, 0.3 mL/min; 22 min, 95:5, 0.3 mL/min. The gradient profile was optimized to improve the peak response and achieve rapid wash-out interference and equilibrate the column with the initial mobile phase condition for the next injection. The total run time was 22 min, and the column oven temperature was 40 °C. The sample injection volume was 5 μL.

The electrospray ionization (ESI) source was operated in positive mode, and the mass spectrometer was operated in the multiple reaction monitoring (MRM) mode. The observed MRM transitions and mass spectrometry settings are summarized in Supplementary Table 1.

Preparation of stock solutions, calibration standards, and quality control samples. Stock solutions. The stock solutions of $^{175}$Lu-DOTA-PSMA-GUL were prepared by diluting 2.1 mg/mL synthesized solution in methanol to 400 μg/mL. The stock solutions of NOTA-PSMA-GUL (internal standard 1, IS1) and esomeprazole (internal standard 2, IS2) were prepared by separately dissolving 10 mg of each in 10 mL of methanol (1 mg/mL).

Calibration standards and quality control samples. For drug analysis in the plasma, calibration curves were constructed by spiking 50 μL of working stock solutions to blank plasma (50 μL each) to provide $^{175}$Lu-DOTA-PSMA-GUL concentrations at 20,000, 10,000, 5000, 1000, 500, 100, 50, and 20 ng/mL. The plasma was spiked with 50 μL of IS1 solution and 150 μL of methanol and mixed on a vortex mixer. The mixture was then centrifuged for 10 min at 4000 rpm (3220 × g), and 100 μL of the supernatant was transferred to a plastic vial. After 100 μL of distilled water was added to the supernatant, the mixture was vortex-mixed for 10 min and 5 μL of the mixture was injected onto the LC–MS/MS. Quality control (QC) samples were prepared by spiking the working drug solutions to blank rat plasma to provide high concentration QC (16,000 ng/mL), middle concentration QC (8,000 ng/mL), low concentration QC (80 ng/mL) and lower limit of quantification (LLOQ) QC (20 ng/mL).

Similarly, calibration standards and QC samples were prepared for drug analysis in urine, feces, and twelve different tissues. Calibration ranges were 100–20,000 ng/mL for urine, 100–5000 ng/mL for feces and tissues. High, middle, and low QC sample concentrations were 16,000, 8000, and 400 ng/mL for urine, 4000, 1600, and 400 ng/mL for feces and tissue matrices.

Sample preparation. For plasma samples, NOTA-PSMA-GUL (internal standard 1, IS1) solution 50 μL was added to 50 μL of the rat plasma. As a precipitation solvent, 200 μL of methanol was added, and the mixture was mixed on a vortex mixer for 10 min, followed by centrifugation for 10 min at 4000 rpm (3220 × g). After taking 100 μL of the supernatant, 100 μL of distilled water was added, vortex-mixed for 10 min. Finally, 5 μL of the prepared mixture was injected onto the LC–MS/MS. Since several plasma samples showed concentrations above the ULOQ, those samples were diluted 10- or 20-fold for analysis.

For urine and fecal homogenate samples, the working IS2 solution 50 μL was added to 50 μL of the homogenate samples. The samples were precipitated with methanol (900 μL) on a vortex mixer for 10 min, followed by centrifugation for 10 min at 4000 rpm (3220 × g). After taking 100 μL of the supernatant, 100 μL of distilled water was added, vortex-mixed for 10 min.

For tissue homogenate samples, the working IS2 solution 50 μL was added to 50 μL of tissue homogenate samples. The samples were precipitated with methanol (400 μL) on a vortex mixer for 10 min, followed by
centrifugation for 10 min at 4,000 rpm (3220 × g). After taking 200 μL of the supernatant, 200 μL of distilled water was added to the supernatant and centrifuged for 10 min again. After the second centrifugation, 100 μL of supernatant and the same volume of distilled water was mixed for 10 min. Finally, 5 μL of the prepared mixture was injected onto the LC–MS/MS.

In vivo pharmacokinetic studies in rats. Animals. Male Sprague–Dawley rats (7 weeks, 190–210 g; DBL Co., Eumsung, Korea) were kept in plastic cages with free access to a standard diet (Youngbio, Seong-nam, Korea) and water. All experiments were performed in accordance with the relevant guidelines and regulations. The animal study protocol was approved by the Institutional Animal Care and Use Committee of Sungkyunkwan University (SKKUIACUC2018-07-25-1). Studies involving animals are reported in accordance with ARRIVE guidelines (https://arriveguidelines.org).

Pharmacokinetics of 175Lu-DOTA-PSMA-GUL after i.v. bolus injection. Freshly prepared 175Lu-DOTA-PSMA-GUL solution (2.1 mg/mL) was administered by i.v. bolus injection via the penile vein (n = 5–7) at three doses of 1, 2, and 5 mg/kg. Approximately 0.3 mL of the jugular venous blood samples were collected at predetermined times after i.v. injection. Plasma samples were harvested by centrifugation of the blood samples at 3220 × g for 10 min. Urine and feces samples were collected at 4, 8, 12, and 24 h after i.v. injection. All samples were stored at -70 °C until analysis.

Tissue distribution of 175Lu-DOTA-PSMA-GUL after i.v. infusion. Tissue distribution of 175Lu-DOTA-PSMA-GUL was examined under two different steady-state conditions after i.v. infusion of 175Lu-DOTA-PSMA-GUL. Two target steady-state plasma concentrations (Css) were set as 3000 and 6000 ng/mL. Rats were surgically cannulated with polyethylene tubing (0.58 mm i.d. and 0.96 mm o.d.; Natsume, Tokyo, Japan) in the left jugular vein for blood sampling and femoral vein for i.v. injection and infusion. After one day of recovery, 175Lu-DOTA-PSMA-GUL was administered by i.v. injection as a loading dose (LD) and i.v. infusion for 3 h to achieve the targetCss. The i.v. bolus LD and i.v. infusion rates (K0) were calculated by LD = Css,target·Vss and K0 = Css,target·CL, respectively. The volume of distribution (Vss, 0.20 L/kg) and clearance (CL, 607.55 mL/h/kg) of 175Lu-DOTA-PSMA-GUL were obtained from the i.v. injection study. The calculated LD was 0.60 mg/kg and 1.20 mg/kg for the targetCss of 3,000 ng/mL and 6,000 ng/mL, respectively. The calculated K0 was 1.82 mg/h/kg and 3.65 mg/h/kg for the targetCss of 3,000 ng/mL and 6,000 ng/mL, respectively.

Blood samples were collected at 1.5, 2, 2.5, and 3 h during i.v. infusion, and centrifuged at 3,200 × g for 10 min. At the end of the infusion, rats were sacrificed, and brain, lung, heart, spleen, small intestine, stomach, kidney, liver, prostate, fat, muscle, and testis were excised and immediately homogenized in normal saline. All samples were stored at -70 °C until analysis.

Non-compartmental analysis. The plasma concentration–time data were analyzed by non-compartmental method using Phoenix’ WinNonlin’ (Pharsight, NC, USA). The fraction of 175Lu-DOTA-PSMA-GUL excreted into urine (Frurine) and feces (Frfeces) were calculated by the ratio of the total amount of drug excreted in the urine and feces to the fraction of the dose, respectively. The tissue-to-plasma partition coefficients (Kp) were calculated as the tissue-to-plasma concentration ratios.

Dose proportionality. Dose proportionality was tested for Cmax, AUCall, and AUCinf based on power model. Assuming the natural logarithm of the pharmacokinetic parameter is linearly related to the natural logarithm of dose as in the following equation: ln( PK parameter ) = β0 + β1 × ln (dose), the slope coefficient (β1) and its two-sided 95% confidence intervals (CI) were estimated.

Statistical analysis. The data were statistically tested by the unpaired t-test to compare between two means and by one-way analysis of variance (ANOVA) followed by scheffe or games-howell post hoc test. The statistical significance level was set at p < 0.05. All the statistical analyses were performed by using IBM® SPSS® Statistics 26 (IBM, Armonk, NY, USA).

Results
Development of LC–MS/MS assay for 175Lu-DOTA-PSMA-GUL in rat biomatrices. The product ion mass spectra of protonated 175Lu-DOTA-PSMA-GUL, NOTA-PSMA-GUL (IS1), and esomeprazole (IS2) are shown in Supplementary Fig. 1. In the full scan of mass spectra, doubly charged ions, [M + 2H]2+ of 175Lu-DOTA-PSMA-GUL at m/z 522.1 and NOTA-PSMA-GUL were most intense, which was likely due to their complex structures. The most abundant product ions were observed at m/z 148 and 188.9 for 175Lu-DOTA-PSMA-GUL and NOTA-PSMA-GUL, respectively. Therefore, the MRM transitions of m/z 522.1 → 148.0 for 175Lu-DOTA-PSMA-GUL and m/z 385.8 → 188.9 for NOTA-PSMA-GUL were selected and monitored. For esomeprazole, the MRM transition of precursor to product ion pair was m/z 346.1 → 198.0.

The sample preparation and chromatographic conditions were optimized to increase the sensitivity of the analyte. The recovery was significantly enhanced when methanol was used as a precipitation solvent compared to acetonitrile. Thus, a single step protein precipitation with methanol was developed for the extraction of both analyte and internal standard (IS) from the biological samples. NOTA-PSMA-GUL was initially used as IS for the development of analytical method in the plasma. However, when the method was applied to other biological matrices, the recovery of NOTA-PSMA-GUL was poor (< 60%) and variable depending on the matrices. Thus, we have tried other compounds, including rebamipide, ketoprofen, diclofenac, aceclofenac, and esomeprazole, as
an internal standard. Since esomeprazole showed higher recovery and acceptable reproducibility, it was selected as an internal standard for urine, feces, and tissue samples. For chromatographic separation, Agilent Zorbax SB-Aq column (100 × 2.1 mm, i.d., 3.5 μm) resulted in the best chromatographic separation with improved sensitivity after various reverse phase columns were examined. The presence of formic acid in the mobile phase significantly increased the peak response. The use of methanol as an organic solvent was also beneficial compared to acetonitrile. Finally, the gradient profile was optimized to provide the best sensitivity of 175Lu-DOTA-PSMA-GUL with the minimal interference.

Validation of LC–MS/MS assay. The LC–MS/MS assay was validated according to the FDA guidance25. Representative MRM chromatograms of 175Lu-DOTA-PSMA-GUL and IS are shown in Fig. 2. Examination of blank sample, zero sample and other calibrators showed no interfering peaks at the retention times corresponding to the analyte and internal standards in all matrices, indicating the specificity of the assay. The calibration curves were linear over 175Lu-DOTA-PSMA-GUL concentration ranges of 20–20,000 ng/mL for plasma, 100–20,000 ng/mL for urine, and 100–5,000 ng/mL for feces and all tissues with R² > 0.998. The lower limit of quantification (LLOQ) was 20 ng/mL in the plasma and 100 ng/mL in other biological matrices, including urine, feces, and tissue samples. The signal-to-noise (S/N) ratios at LLOQ concentration were over 11.7 for all tested biological matrices.

The intra- and inter-day accuracy and precision determined by assaying LLOQ, low, medium, and high QC samples in the plasma, urine, feces, and twelve tissues are shown in Supplementary Table 2. The intra- and inter-day accuracy ranged from 90.96 to 106.82% in all the rat biological matrices. The intra- and inter-day precisions were under 10.22% and 9.22%, respectively. The intra-day and inter-day accuracy and precision were all within the ranges recommended by the FDA25.

Figure 2. Representative MRM chromatograms of 175Lu-DOTA-PSMA-GUL (analyte) and internal standard (IS) obtained from blank matrix (left) and blank matrix spiked with 175Lu-DOTA-PSMA-GUL at LLOQ and IS (right) for plasma (A), urine (B), feces (C), and prostate (D).
Analytical validation data including stability and process efficiency are shown in Supplementary Tables 3 and 4. Compared with the theoretical concentrations, 175Lu-DOTA-PSMA-GUL concentrations in each biological matrix did not deviate significantly after storage under four different conditions including short-term (room temperature for 4 h), long-term (−70 °C for two weeks), freeze–thaw (4 cycles), and autosampler (4 °C for 24 h) (Supplementary Table 3). These data indicates that 175Lu-DOTA-PSMA-GUL was stable in each biological matrix under the sample collection and assay conditions. The process efficiency in each biological matrix is generally consistent (Supplementary Table 4). Although the process efficiency of 175Lu-DOTA-PSMA-GUL was found to be lower in several tissues such as lung, small intestine, kidney, and liver, they were consistent and reproducible as indicated by the small CV%. FDA guidance also indicated that “Recovery need not be 100 percent, but the extent of the recovery of an analyte and of the ISs should be consistent and reproducible.”25 For plasma samples, the dilution integrity was evaluated for a 10- and 20-fold dilution of QC samples at 40,000 ng/mL, which was two times higher than ULOQ, with blank matrix. The accuracy for dilution integrity was 105.56% and 102.21%, while precision was 1.03% and 2.39% for tenfold and 20-fold dilution, respectively (n = 3, each).

Pharmacokinetics of 175Lu-DOTA-PSMA-GUL in rats. A drug solution of 175Lu-DOTA-PSMA-GUL was prepared immediately before drug administration and tested by HPLC–UV. The purity of 175Lu-DOTA-PSMA-GUL was > 95%. The peak response of 175Lu-DOTA-PSMA-GUL was consistent (97.1 ± 8.0%) compared to the reference, indicating that 175Lu-DOTA-PSMA-GUL was uniformly prepared.

Figure 3 shows the average plasma concentration of 175Lu-DOTA-PSMA-GUL vs. time profiles obtained after intravenous injection of 1, 2, and 5 mg/kg 175Lu-DOTA-PSMA-GUL in rats (n = 5–7).

| Parameters     | 1 mg/kg  | 2 mg/kg  | 5 mg/kg  |
|----------------|----------|----------|----------|
| t1/2 (h)       | 0.32 ± 0.02 | 0.30 ± 0.03 | 0.33 ± 0.09 |
| C0 (ng/mL)     | 9267.42 ± 2673.59 | 14,960.22 ± 3104.40* | 46,720.92 ± 13,829.91*† |
| AUC0-12h (ng·h/mL) | 1841.19 ± 266.36 | 3029.00 ± 350.80* | 8038.10 ± 1055.28*† |
| AUCinf (ng·h/mL) | 1857.48 ± 270.08 | 3047.45 ± 346.00* | 8076.44 ± 1063.99*† |
| Vc (L/kg)      | 0.25 ± 0.03 | 0.29 ± 0.05 | 0.30 ± 0.09 |
| CL (mL/min/kg) | 9.13 ± 1.30 | 11.04 ± 1.15 | 10.46 ± 1.30 |
| MRT (h)        | 0.34 ± 0.02 | 0.32 ± 0.03 | 0.32 ± 0.02 |
| Vss (L/kg)     | 0.19 ± 0.03 | 0.21 ± 0.04 | 0.20 ± 0.03 |
| Furex (%)      | 58.71 ± 21.26 | 54.59 ± 25.98 | 59.89 ± 22.82 |
| Ffeces (%)     | 5.46 ± 4.11 | 1.08 ± 0.76 | 6.41 ± 3.68 |

Table 1. Average non-compartmental pharmacokinetic parameters and excretion ratio of 175Lu-DOTA-PSMA-GUL after intravenous injection in rats (n = 5–7). *p < 0.05 vs. 1 mg/kg; †p < 0.05 vs. 2 mg/kg.
elimination half-life of $^{175}$Lu-DOTA-PSMA-GUL was less than 0.33 h, and $^{175}$Lu-DOTA-PSMA-GUL was not detected in the plasma after 4 h of i.v. injection. The average CL and $V_{ss}$ of $^{175}$Lu-DOTA-PSMA-GUL were estimated to be 10.13 mL/min/kg and 0.20 L/kg, respectively.

Dose proportionality. The plasma concentration at time zero ($C_0$), the area under the plasma concentration–time curve from time zero to last time point (AUC all), and AUC from time zero to infinity (AUC inf) increased with the increase of $^{175}$Lu-DOTA-PSMA-GUL dose. Assessment of dose proportionality by the power model showed that the slope estimates ($\beta_1$) were 1.012 [95% CI 0.830–1.194] for $C_0$, 0.923 [95% CI 0.825–1.021] for AUC all, and 0.921 [95% CI 0.822–1.019] for AUC inf. Thus, the dose proportionality was statistically significant for all tested systemic exposure parameters, i.e., $C_0$, AUC all, and AUC inf, indicating the linear pharmacokinetics of $^{175}$Lu-DOTA-PSMA-GUL over i.v. dose range from 1 to 5 mg/kg.

Excretion of $^{175}$Lu-DOTA-PSMA-GUL. The excretion of $^{175}$Lu-DOTA-PSMA-GUL via urine and feces was determined by analyzing $^{175}$Lu-DOTA-PSMA-GUL concentrations in the urine and feces samples for 24 h after i.v. injection. The fraction of $^{175}$Lu-DOTA-PSMA-GUL excreted into urine ($F_{\text{urine}}$) and feces ($F_{\text{feces}}$) are also shown in Table 1. The average $F_{\text{urine}}$ of $^{175}$Lu-DOTA-PSMA-GUL was 54.59–59.89%, indicating that renal excretion may be the major elimination pathway of $^{175}$Lu-DOTA-PSMA-GUL. On the other hand, the average $F_{\text{feces}}$ of $^{175}$Lu-DOTA-PSMA-GUL was 1.08–6.41%, indicating the marginal excretion of into feces.

Tissue distribution of $^{175}$Lu-DOTA-PSMA-GUL. Steady state. Tissue distribution of $^{175}$Lu-DOTA-PSMA-GUL was assessed at steady state following i.v. infusion at two dose levels that aimed to obtain $C_{\text{ss,target}}$ of 3,000 ng/mL and 6,000 ng/mL. An i.v. bolus loading dose was also administered to rapidly achieve the target steady state concentration.

Average plasma $^{175}$Lu-DOTA-PSMA-GUL concentrations determined following simultaneous i.v. bolus injection (loading bolus dose 0.60 and 1.20 mg/kg) and continuous i.v. infusion (infusion rate 1.82 and 3.65 mg/h/kg) are shown in Fig. 4. Plasma concentrations of $^{175}$Lu-DOTA-PSMA-GUL appeared stable at approximately 3,000 ng/mL and 6,000 ng/mL from 1.5 h following i.v. infusion. These data indicate that the steady-state has been reached, and the intended steady-state plasma concentrations have been achieved.

Tissue distribution. After confirming that the steady state has been achieved, tissue samples were collected to assess the tissue distribution of $^{175}$Lu-DOTA-PSMA-GUL. The average tissue concentrations of $^{175}$Lu-DOTA-PSMA-GUL and the respective $K_p$ in twelve different tissues at steady state are shown in Fig. 5 and Table 2. The tissue concentrations are presented in ng/g tissue, which was calculated as the measured concentration in the tissue homogenate by LC–MS/MS (ng/mL) divided by the density of tissue homogenate (g tissue/mL). The tissue concentration of $^{175}$Lu-DOTA-PSMA-GUL was the highest in the kidneys, followed by the prostate, lung, liver, small intestine, heart, spleen, testis, muscle, fat, and stomach. $^{175}$Lu-DOTA-PSMA-GUL was not detected in the brain. Accordingly, the average $K_p$ values of kidneys and prostate were 2.58 and 1.20, which are greater than 1.0
and significantly higher than those of other tissues, indicating that $^{175}\text{Lu}$-DOTA-PSMA-GUL is highly distributed into these tissues. The average $K_P$ for other tissues was less than 0.34.

**Discussion**

This study aimed to evaluate the pharmacokinetics of an intact PSMA-targeted ligand in rats. The introduction of an isotopically labeled compound combined with mass spectrometry allowed highly sensitive and specific bioanalysis as well as a full characterization of the pharmacokinetics.

A robust quantification method of $^{175}\text{Lu}$-DOTA-PSMA-GUL has been developed using LC–MS/MS to analyze the intact $^{175}\text{Lu}$-DOTA-PSMA-GUL in the biological fluids, including plasma, excreta, and 12 different tissues. Although sensitive mass spectrometry-based analytical methods have become essential for any pharmacokinetic studies for radio-inactive compounds, there have been limited attempts to actively utilize LC–MS/MS for radioactive ligands. Conventional analytical methods such as LC–MS/MS for the intact compound might be either infeasible due to the radioactivity of the radioligands or not demanding due to the presence of alternatives such as radioactivity and imaging techniques. Nevertheless, the radioactivity assays and imaging techniques are primarily indirect and may result in inaccurate results because they cannot discern the radionuclide located in the intact drug or in the metabolites$^{20}$. Therefore, we utilized a stable isotope-labeled analog, $^{177}\text{Lu}$-DOTA-PSMA-GUL, combined with LC–MS/MS to characterize the pharmacokinetic behavior of a PSMA-targeted radioligand, $^{177}\text{Lu}$-DOTA-PSMA-GUL.
By using the LC–MS/MS, the pharmacokinetic profiles and excretion of $^{175}$Lu-DOTA-PSMA-GUL were first examined after i.v. bolus injection in rats. Following i.v. injection, $^{175}$Lu-DOTA-PSMA-GUL exhibited multi-exponential decline with a relatively short elimination half-life ($t_{1/2}$) of 0.30–0.33 h. The rapid clearance from the tissues except the kidneys and prostate were lower than half of the plasma concentration (Table 2). The limited GUL from 1 to 5 mg/kg. Over 50% of the administered $^{175}$Lu-DOTA-PSMA-GUL was excreted into the urine, the KP of $^{175}$Lu-DOTA-PSMA-GUL in the prostate may be mainly associated with the prostate targeting property of GUL into tissues may be limited. Indeed, the observed concentrations of $^{175}$Lu-DOTA-PSMA-GUL in all tested tissues obtained following simultaneous intravenous bolus injection (loading bolus dose 0.60 and 1.20 mg/kg) plus continuous intravenous infusion (infusion rate 1.82 and 3.65 mg/h/kg) in rats (n = 5, each). *Plasma concentrations are in ng/mL; BLOQ, below the lower limit of quantification.

Table 2. Average concentrations of $^{175}$Lu-DOTA-PSMA-GUL and tissue to plasma partition coefficient ($K_p$) in tissues obtained following simultaneous intravenous bolus injection (loading bolus dose 0.60 and 1.20 mg/kg) plus continuous intravenous infusion (infusion rate 1.82 and 3.65 mg/h/kg) in rats (n = 5, each).

| Tissues     | Concentration (ng/g) | Tissue to plasma coefficient ($K_p$) |
|-------------|----------------------|--------------------------------------|
|             | $\text{CSS}_{\text{target}} = 3000$ ng/mL | $\text{CSS}_{\text{target}} = 6000$ ng/mL |
| Plasma*     | 2.845.62 ± 111.43     | 5.713.2 ± 523.23                    |
| Brain       | BLOQ                 | BLOQ                                 |
| Lung        | 1.962.76 ± 287.82     | 1.480.52 ± 464.64                   |
| Heart       | 6.457.67 ± 204.29     | 7.357.5 ± 453.10                    |
| Spleen      | 5.413 ± 52.33         | 9.320 ± 368.50                      |
| Small intestine | 7.417 ± 507.55       | 16.362 ± 1273.92                    |
| Stomach     | 27.26 ± 95.71         | 61.23 ± 161.18                      |
| Kidney      | 7.253 ± 665.80        | 14.455 ± 1272.17                    |
| Liver       | 4.94 ± 34.61          | 1.881 ± 267.48                      |
| Fat         | 3.608 ± 55.49         | 4.065 ± 77.17                       |
| Muscle      | 3.42 ± 188.70         | 6.217 ± 419.81                      |
| Prostate    | 2.433.69 ± 2292.84    | 8.550 ± 732.82                      |
| Testis      | 5.014 ± 122.39        | 8.773 ± 252.52                      |

In summary, the pharmacokinetics of a PSMA-targeted ligand, $^{175}$Lu-DOTA-PSMA-GUL, including excretion and tissue distribution, are characterized for the first time by applying LC–MS/MS. The present data indicate that $^{175}$Lu-DOTA-PSMA-GUL exhibited linear pharmacokinetics over the dose range from 1 to 5 mg/kg and renal excretion of $^{175}$Lu-DOTA-PSMA-GUL is the primary elimination route of $^{175}$Lu-DOTA-PSMA-GUL, whereas the excretion into feces was insignificant. These results are in good agreement with the clinical reports that the majority of $^{177}$Lu-PSMA-617 was eliminated by urine (approximately 50%) and only 1–5% by fecal excretion in patients with PSMA-positive tumor phenotype.

By using the LC–MS/MS, the pharmacokinetic profiles and excretion of $^{175}$Lu-DOTA-PSMA-GUL were first examined after i.v. bolus injection in rats. Following i.v. injection, $^{175}$Lu-DOTA-PSMA-GUL exhibited multi-exponential decline with a relatively short elimination half-life ($t_{1/2}$) of 0.30–0.33 h. The rapid clearance from the systemic circulation of PSMA ligands has already been recognized. Our data also showed that the systemic exposure represented by $C_{0}$, AUC$_{all}$ and AUC$_{inf}$ was dose-proportional over the doses of $^{177}$Lu-DOTA-PSMA-GUL from 1 to 5 mg/kg. Over 50% of the administered $^{175}$Lu-DOTA-PSMA-GUL was excreted into the urine, suggesting that renal excretion is the primary elimination route of $^{175}$Lu-DOTA-PSMA-GUL, whereas the excretion into feces was insignificant. These results are in good agreement with the clinical reports that the majority of $^{177}$Lu-PSMA-617 was eliminated by urine (approximately 50%) and only 1–5% by fecal excretion in patients with PSMA-positive tumor phenotype.

The distribution of $^{175}$Lu-DOTA-PSMA-GUL was assessed at two steady state conditions after intravenous infusions of $^{175}$Lu-DOTA-PSMA-GUL in rats. Although PSMA targeted radioligands are reported to be highly distributed to PSMA expressing tumors and normal organs like kidneys via imaging technology, direct experimental evidence of their distribution into various tissues has not been reported. Moreover, in the present study, the in vivo tissue distribution of $^{175}$Lu-DOTA-PSMA-GUL has been determined at steady states (Fig. 4). At steady state, the rate of drug input, i.e., intravenous infusion, is equal to the rate of drug output, i.e., elimination, resulting in no net change in the amount of drug in the body. Thus, steady state conditions allow evaluating the true extent of tissue distribution when the plasma and tissue concentration do not change, which may be affected by confounding factors otherwise.

The distribution of $^{175}$Lu-DOTA-PSMA-GUL into tissues was estimated to be low, i.e., 0.20 L/kg (Table 1), indicating that the distribution of $^{175}$Lu-DOTA-PSMA-GUL into tissues may be limited. Indeed, the observed concentrations of $^{175}$Lu-DOTA-PSMA-GUL in all tested tissues except the kidneys and prostate were lower than half of the plasma concentration (Table 2). The limited tissue distribution of $^{175}$Lu-DOTA-PSMA-GUL is likely due to its large molecular weight, preventing the passage across the cell membrane. Nevertheless, our data clearly showed that the distribution of $^{175}$Lu-DOTA-PSMA-GUL into the kidneys and prostate was significantly higher than other tissues (Table 2 and Fig. 5). The kidneys and prostate are the well-known tissues where PSMA is expressed. The high distribution in the kidneys may also be attributed to that the primary elimination route of $^{175}$Lu-DOTA-PSMA-GUL is urinary excretion. As presented in Table 1, more than half of the $^{175}$Lu-DOTA-PSMA-GUL is excreted into the urine. On the other hand, the high $K_p$ of $^{175}$Lu-DOTA-PSMA-GUL in the prostate may be mainly associated with the prostate targeting property of $^{175}$Lu-DOTA-PSMA-GUL. The GUL domain of $^{175}$Lu-DOTA-PSMA-GUL binds explicitly to PSMA that is overexpressed in the prostate cancer cells, providing the prostate targeting property. These tissue distribution data indicate that $^{175}$Lu-DOTA-PSMA-GUL may be specific and effective for the treatment of prostate cancer.

In summary, the pharmacokinetics of a PSMA-targeted ligand, $^{175}$Lu-DOTA-PSMA-GUL, including excretion and tissue distribution, are characterized for the first time by applying LC–MS/MS. The present data indicate that $^{175}$Lu-DOTA-PSMA-GUL exhibited linear pharmacokinetics over the dose range from 1 to 5 mg/kg and renal excretion is the primary elimination route. The prostate-specific targeting property of $^{175}$Lu-DOTA-PSMA-GUL was also demonstrated. The developed LC–MS/MS assay and the in vivo pharmacokinetic data would provide useful information for the further development of $^{175}$Lu-DOTA-PSMA-GUL and other structural analogs as a novel therapeutic agent for the treatment of prostate cancer.
Data availability
The datasets generated and analyzed during this study are available from the corresponding author upon reasonable request.

Received: 25 February 2022; Accepted: 2 September 2022
Published online: 14 September 2022

References
1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).
2. Litwin, M. S. & Tan, H.-J. The diagnosis and treatment of prostate cancer: A review. JAMA 317, 2532–2542. https://doi.org/10.1001/jama.2017.7248 (2017).
3. Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10, 63–89. https://doi.org/10.14790/wjon1191 (2019).
4. Kalra, S. et al. The implications of ageing and life expectancy in prostate cancer treatment. Nat. Rev. Urol. 13, 289–295. https://doi.org/10.1038/nrurol.2016.52 (2016).
5. Kinoshita, Y. et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 30, 628–636. https://doi.org/10.1007/s00268-005-0544-5 (2006).
6. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81–85 (1997).
7. Perner, S. et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum. Pathol. 38, 696–701. https://doi.org/10.1016/j.humpath.2006.11.012 (2007).
8. Moon, S. H. et al. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA). Nanomedicine 12, 871–879. https://doi.org/10.1016/j.nano.2015.12.368 (2016).
9. Kratochwil, C. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 57, 1170–1176. https://doi.org/10.2967/jnumed.115.171397 (2016).
10. Eiber, M. et al. Prostate-specific membrane antigen ligands for imaging and therapy. J. Nucl. Med. 58, 675–765. https://doi.org/10.2967/jnumed.116.186767 (2017).
11. Alshar-Oromieh, A. et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J. Nucl. Med. 56, 1697–1705. https://doi.org/10.2967/jnumed.115.161299 (2015).
12. Hofman, M. S. et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 19, 825–833. https://doi.org/10.1016/S1470-2045(18)30198-0 (2018).
13. Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107322 (2021).
14. Calais, J. et al. Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial. J. Clin. Oncol. 38, 5549–5549. https://doi.org/10.1200/JCO.2020.38.15_suppl.5549 (2020).
15. Yadav, M. P. et al. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients. PLoS ONE 16, e0251375. https://doi.org/10.1371/journal.pone.0251375 (2021).
16. Kabasakal, L. et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imag. 42, 1976–1983. https://doi.org/10.1007/s00259-015-3125-3 (2015).
17. Fendler, W. P. et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin 55, 123–128 (2016).
18. Khawar, A. et al. Prediction of normal organ absorbed doses for [177Lu]Lu-PSMA-617 using [44Sc]Sc-PSMA-617 pharmacokinetics in patients with metastatic castration resistant prostate carcinoma. Clin. Nucl. Med. 43, 486–491. https://doi.org/10.1097/RLU.0000000000002102 (2018).
19. Violet, J. et al. Dosimetry of [177]Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J. Nucl. Med. 60, 517–523. https://doi.org/10.2967/ inumid.118.213932 (2019).
20. Bergstrom, M. & Langstrom, B. Pharmacokinetic studies with PET. Prog. Drug Res. 62, 279–317. https://doi.org/10.1007/3-7643-7426-8_8 (2005).
21. Lu, S. X. et al. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J. Pharm. Sci. 94, 788–797. https://doi.org/10.1010/jps.202059 (2005).
22. de Zanger, R. M. S., Chan, H. S., Breeman, W. A. P. & Blois, E. Maintaining radiocohemical purity of [177Lu]-Lu-DOTA-PSMA-617 for PRRT by reducing radiolysis. J. Radioanal. Nucl. Chem. 321, 285–291. https://doi.org/10.1007/s10967-019-06573-y (2019).
23. Schellekens, R. C. A., Stellara, F., Woerdenbag, H. J., Frijlink, H. W. & Kosterink, J. G. W. Applications of stable isotopes in clinical pharmacology. Br. J. Clin. Pharmacol. 72, 879–897. https://doi.org/10.1111/bjcp.13659215.04071.x (2011).
24. Kim, T. H. et al. Determination of acrylamide and glycidamide in various biological matrices by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. Talanta 131, 46–54. https://doi.org/10.1016/j.talanta.2014.07.042 (2015).
25. US FDA. (Center for Drug Evaluation and Research US Department of Health and Human Services) (Rockville, MD, 2018).
26. Wang, Z. et al. Single low-dose injection of evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug. Chem. 29, 3213–3221. https://doi.org/10.1021/acs.bioconjchem.8b00556 (2018).

Author contributions
T.H.K., S.S., and B.S.S. conceptualized the study. C.H.S., K.K., E.K., B.J., M.-S.L., and J.J. conducted a research and investigation. C.H.S. and B.S.S. prepared the original draft and S.S. and B.S.S. revised and edited the manuscript. All authors reviewed and approved the final manuscript.

Competing interests
K.K., E.K., B.J., M.-S.L., and J.J. are employees of CellBion Co., Ltd.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-19700-9.
